Experimental Gene Therapy Reduced Seizures But Raised Safety Concerns

What was studied

This report looked at an experimental gene-targeting treatment in two 2-year-old girls with a very severe form of KCNT1-related epileptic encephalopathy called epilepsy of infancy with migrating focal seizures. Both children had the same KCNT1 gene change, p.R474H, which the abstract describes as a severe, recurrent pathogenic variant.

The treatment was an antisense oligonucleotide designed to lower KCNT1 expression. It was not tailored to one specific mutation. The medicine was given into the spinal fluid by lumbar puncture (intrathecal delivery).

What they found

After treatment, both children had a significant reduction in seizure frequency and intensity. However, both also developed ventricular enlargement or hydrocephalus after the investigational treatment. In one child, this was associated with redirection of goals of care. The authors describe this as a potential monitorable toxicity of some intrathecal antisense oligonucleotides.

Limits of the evidence

This was only a report of two patients, so it cannot show how well the treatment works or how safe it is overall. There was no comparison group, and both children had the same variant, so the findings may not apply to other KCNT1 changes or other ages. The abstract does not give detailed numbers on seizure reduction, timing, long-term outcomes, or whether the ventricular enlargement or hydrocephalus was definitely caused by the treatment.

For families and caregivers

For families, this study suggests that a treatment aimed at KCNT1 might reduce seizures in some children with this very severe epilepsy. At the same time, it raises an important safety concern, because both treated children developed ventricular enlargement or hydrocephalus. This means the approach remains very experimental and would need careful specialist monitoring and more evidence.

What to watch next

Important next steps would include studying more patients, longer follow-up, and clearer safety data, especially on ventricular enlargement or hydrocephalus and how to monitor for it.

Terms in this summary

antisense oligonucleotide

A lab-made genetic medicine designed to lower or change how much of a specific gene product the body makes.

KCNT1

A gene that helps control electrical activity in brain cells.

epileptic encephalopathy

A severe epilepsy in which seizures and abnormal brain activity are linked with major problems in development and brain function.

intrathecal

Given into the fluid around the spinal cord, usually by lumbar puncture.

lumbar puncture

A procedure that uses a needle in the lower back to reach spinal fluid.

hydrocephalus

A buildup of fluid in or around the brain that can increase pressure and enlarge fluid spaces.

de novo variant

A genetic change that is new in the child and was not inherited from a parent.